Enamine, Pcovery Extend Drug Discovery Collaboration
News Nov 23, 2016
Enamine Ltd. and Danish biotech company Pcovery, have announced that they have extended their collaboration for the discovery of new drugs for the treatment of invasive fungal infections and platform technology development.
Since 2014, Enamine’s role has gradually evolved from a hit-finding library provider to a trusted partner in the field of broadly applicable chemistry services. A rigorous evaluation and selection process carried out at Pcovery identified Enamine as a reliable partner that provides state-of-the-art chemistry solutions at any level from synthesis of small compound libraries and singletons, through route scouting and process optimisation as well as scale-up of leads.
Under the terms of the collaboration, Pcovery’s dedicated full time equivalent (FTE) team benefit from instant access to Enamine’s inventory of building blocks, a collection that has been recognised for its impeccable structural quality and significant innovative components. All project reagent costs are covered by the FTE rate in place. While Enamine’s experts actively participate in new composition of matter generation, the IP produced in the collaboration solely belongs to Pcovery.
Asked about the collaboration, William Dalby-Brown, Chief Operator Officer at Pcovery commented: “With a plethora of CROs in the market, finding the right partner remains a challenge. Headcount is not everything; chemists’ skills, creativity, experience and access to the impressive stock of contemporary building blocks were the most important factors that ultimately led us to choose Enamine. Their remarkable work in synthesising their collection of building blocks now helps us to accelerate our drug discovery projects. We can pick from their stock building blocks, whereas sourcing in other ways would incur both time and cost. Our strategic partner Enamine is demonstrating a key role in Pcovery’s successful path towards discovery and development of novel anti-infective drug candidates, with a particularly strong potential for the formation of a defensive IP position.”
“We are delighted to continue our collaboration with Pcovery and advance to the company’s next level,” added Michael Bossert, Head of Strategic Alliances at Enamine, continuing: “First recognition of our expertise came with our offering of library synthesis using our end-capping building blocks and scaffolds received from a CRO that had been working with Pcovery previously. A relationship built on trust was rapidly established with Pcovery, who was further convinced via our high level chemistry service, seamless collaboration communication and positive work environment stimulating fruitful ideas. This collaboration is another validation of Enamine cost effective benefit for early drug discovery activities.”
Story from Enamine Ltd. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018